Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Go back to Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis| ALKERMES (NASDAQ: ALKS) | Delayed: 46.10 -0.78 (1.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.88 | 52 Week High | $80.71 | |||
| Open | $46.14 | 52 Week Low | $27.14 | |||
| Day High | $46.93 | P/E | 354.62 | |||
| Day Low | $45.80 | EPS | $0.13 | |||
| Volume | 1,064,035 | |||||
